← Back

SFJ Pharmaceuticals - SFJ-NSCLC

SFJ-NSCLC and Pfizer collaborated on a Phase III trial of Pfizer's VIZIMPRO® (dacomitinib) for the treatment of non-small cell lung cancer (NSCLC). The kinase inhibitor was approved in the US for the first-line treatment of NSCLC in September 2018.

LocationPleasanton, California
CEORobert DeBenedetto
PartnerKen Haas
Websitewww.sfj-pharma.com